Innoviva Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $440M+22.7% YoYTTM through 30 Jun 2026
Net Income $357.2M+1,427.2% YoYTTM through 30 Jun 2026
Free Cash Flow $189.4MTTM through 30 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 72.2% |
| EBITDA Margin | 40.1% |
| Operating Margin | 39.8% |
| Net Margin | 81.2% |
Returns
23.1%ROE
16.6%ROA
38.8%ROIC
Balance Sheet Health
Debt / Equity0.22x
Current Ratio16.01x
Net Debt-$293.2Mnet cash position
Cash & Equivalents$570.4M
Quality Metrics
Altman Z-Score3.31
Piotroski F-Score5 / 9
FCF Margin43.1%
Rule of 4044.5
Earnings-Beat Rate75.0%
Multi-Year Trend
RevenueFY2025: $411.3M
Diluted EPS$4.31TTMFY2025: $3.30
Dividend
No dividend
Capital Allocation
R&D Spend$28.7M
Capex Intensity0.5%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| Royalty Business | $250.3M | -2.1% | View detailsProvides stable and resilient cash flow. |
| Innoviva Specialty Therapeutics (IST) | $172.1M | +76.5% | View detailsAnticipates $150 million or more in IST U.S. net product sales in 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.